Abstract

This review covers the end of 2019 and the beginning of 2020 and includes treatment of asymptomatic aortic stenosis, role of antisense oligonucleotides, rivaroxaban in transcatheter aortic valve implantation (TAVI), complete revascularization after myocardial infarction (MI) proving superior, study of colchicine in MI, and update of NOBLE trial showing that percutaneous coronary intervention in left main interventions is inferior to coronary artery bypass graft. There were also a number of trials highlighting various aspects of the outcomes of TAVI implants.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call